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Abstract: A library of 3,5-diaryl-1-carbothioamide-pyrazoline (5a–j), N1-phenyl sulfonyl pyrazoline (6a–e) and pyrimidine (7a) analogs of 
combretastatin-A4 were synthesized and evaluated for their in vitro anticancer, anti-inflammatory and antioxidant activity. Results of in vitro 
assay against human breast cancer cell line (MCF-7) showed several compounds endowed with significant cytotoxicity compared to the 
adriamycin, a standard anticancer drug. Among the compounds synthesized, 7a was found to possess significant antiproliferative activity (GI50 
< 0.1 µM) against the MCF-7 cell line as good as adriamycin (GI50 < 0.1 µM) whereas, compounds 6c, 5j and 5g also displayed good cytotoxicity 
(GI50 = 25.3–42.6 µM). Besides this, most active compound 7a was also evaluated against human myeloid leukemia cell line K562 and the 
remarkable result was obtained with GI50 < 0.1 µM, comparable to that of adriamycin (GI50 < 0.1 µM). In addition, all the synthesized compounds 
were evaluated for their anti-inflammatory and antioxidant activity. The percent inhibition studies revealed that most of the compounds were 
found to possess substantial anti-inflammatory and antioxidant activities. 
 





ANCER is a serious and dreadful disease, difficult to 
alleviate. It is clearly understood that cancer is a dis-
ease of the cell cycle, a complex process regulated by four 
consecutive phases: gap 1 (G1), DNA-synthesis (S), gap 2 
(G2) and mitosis (M). The failure to control checkpoints in 
the cell cycle leads to uncontrolled proliferation of cell.[1] 
Chemotherapy is still one of the ways for the treatment of 
cancer. The currently available anticancer agents mani-
fested undesirable side effects such as low bioavailability, 
toxicity, and drug-resistance.[2] Thus, the discovery of new, 
effective and selective anticancer agents is still a challenge 
in medicinal chemistry. Nevertheless, understanding the 
molecular mechanism involved in cancers can help to pro-
cure novel anticancer agent. One such approach is to target 
microtubule, a dynamic structure that elongates or shrinks 
with the addition or exclusion of tubulin proteins.[3] It is also 
an important cytoskeletal filament crisscrossing the cyto-
plasm of all the eukaryotic cells and perform a vital cellular 
function such as separation of the chromosome during 
mitosis, shape maintenance and vesicle transport. As a 
result, agents that interact at the interface of α,β-dimers of 
tubulin, that is, at the colchicine binding site, inhibit tubulin 
assembly into microtubules. Combretastatins, derived from 
the bark of the African willow tree, Combretum caffrum,[4] 
have received considerable importance due to their ability 
to prevent cancer cell growth. Combretastatin-A4 (1, CA-4, 
Figure 1) in particular, is an effective antivascular and anti-
mitotic agent, which inhibit tubulin polymerization by bind-
ing to colchicine binding site.[5] Consequently, lack of 
microtubule in the metaphase of the cell cycle halts mitotic 
spindle formation.[6] Besides, it alters endothelial cell struc-
ture and vascular permeability, resulting in vascular col-
lapse and tumor necrosis.[2,7] Despite the potent cytotoxic 
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major limitation of high liphophilicity and low solubility in 
aqueous media to develop it as a possible anti-tumor 
agent.[8] The aforementioned physicochemical restriction 
and the simple structural template of combretastatin-A4 
has led to design many structural analogs to improve in vivo 
efficacy, such as the water-soluble phosphate prodrugs of 
CA-4, an amino analog (2, Figure 1) and an amino acid 
derivatives,[9] which have shown remarkable potency. Fur-
thermore, SAR studies reveal that the cis-configuration of 
the two benzene rings and 3,4,5-trimethoxy substituent on 
the A-ring of CA-4 are requisite for potent cytotoxicity.[10] 
This indeed has promoted researchers across the world to 
focus on the design of CA-4 analogs by altering the bridge-
head linker and the B-ring of the CA-4 in order to augment 
the bioavailability and antitumor activity. A broad range of 
structural analogs of CA-4 have been reported, which 
include substitution on B-ring in the combretastatin frame-
work with different heterocycles [11] and replacing the stil-
bene bridgehead linker with different functional groups, for 
example, α,β-unsaturated ketone,[12] and 1,3-disubstituted 
three-carbon linker.[13] 
 Pyrazolines are the rich class of five-member 
heterocycles comprise a wide range of pharmacological 
activities including anti-inflammatory,[14,15] antitumor,[16] 
MAO-B inhibitors[17] and antioxidant activity.[18] Recently, 
pyrazoline bearing 3,4,5-trimethoxy phenyl moiety 
reported as a potent anti-inflammatory agent (3, Figure 
1).[19] On the other hand, 2,4,5-trimethoxy chalcones, their 
analogues 2,4,5-trimethoxy-2’,5’-dihydroxychalcone, and  
hydrazone bearing a 3,4,5-trimethoxy benzyl have  shown 
superior DPPH radical scavenging activities (4, Figure 1).[20] 
Taking into consideration the aforementioned reports, and 
in continuation of our earlier efforts on development of 
anticancer, antioxidant and anti-inflammatory agents,[21,22] 
we herein, intended to report combretastatin analogs by 
altering stilbene bridgehead linker (Scheme 1). 
 
EXPERIMENTAL 
Materials and Methods 
All the chemicals and solvents used were of analytical grade 
and used without purification. All the reactions were mon-
itored by thin layer chromatography, (TLC silica gel 60 F254 
by Merck) and were visualized under a UV lamp and using 
iodine vapors. The melting points were ascertained with a 
digital thermometer and are uncorrected. IR spectra were 
recorded on FT-IR spectrometer (Perkin Elmer). 1H NMR 
spectra were recorded on Bruker DRX FT spectrometer at 
200 MHz and 400 MHz using CDCl3 / DMSO-d6 as a solvent. 
Chemical shift values recorded are mentioned in parts per 
million (ppm) and observed downfield from TMS, while 
coupling constants (J) are referred to in hertz (Hz). 
Abbreviations used in the splitting pattern were as follows: 
s = singlet, d = doublet, t = triplet, q = quartet, qu = quintet 
and m = multiplet. The mass spectra were determined on 
Shimadzu LCMS-2010 EV instrument. 
Synthesis 
GENERAL PROCEDURE FOR THE PREPARATION OF  
3,5-DIARYL-1-CARBOTHIOAMIDE-PYRAZOLINE (5a–j) 
To a suspension of 5-(4,5-dihydro-3-(3,4,5-trimethoxy-
phenyl)-1H-pyrazol-5-yl)-2-methoxyphenol 4a (1 mmol) in 
5 mL absolute ethanol, substituted phenyl isothiocynate (1 
mmol) was added and the mixture was stirred at reflux. The 
progress of the reaction was monitored by TLC. After com-
pletion of reaction (1h), the reaction mixture was allowed 
to cool at room temperature. The solid precipitated was fil-
tered, washed with hot ethanol (2x3mL), and dried under 





Yield: 90 %; MP: 218 °C; MF: C27H29N3O6S; IR (KBr, cm–1): 
3390 (OH), 3322 (NH), 2926 (C=C–H), 2834 (C–H), 1594 
(C=N), 1568 (C=C), 1348 (C=S), 1220 and 1069 (C–O); 1H 
NMR (CDCl3, 200 MHz): δ = 3.252 (d, 1H, J = 9.2 Hz, –CH2–
pyrazoline), 3.753–3.704 (m, 9H, OCH3), 3.802–3.704 (m, 
1H, –CH2–pyrazoline), 3.845 (s, 6H, OCH3), 5.874 (d,1H, J = 
4.6 Hz; –CH–pyrazoline), 6.589 (s, 2H, ArH), 6.852 (d, 1H, J 
= 4.4Hz, ArH), 6.914 (d, 2H, J = 4.2 Hz, ArH), 7.256 (s, 2H, 
ArH), 7.341 (d, 2H, J = 4.2 Hz, ArH), 8.985 (s, 1H, ArOH), 
9.985 (s, 1H, NH); 13C NMR (100 MHz, CDCl3): ): = 42.8, 
55.44,56, 56.34, 61, 63, 104.23, 111, 111.40, 114, 118, 
126.21, 127.23, 132, 135.36, 141, 146.96, 146.99, 153.46, 





Yield: 92 %; MP: 270 °C; MF: C26H26N3O5FS; IR (KBr, cm–1): 
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(C=N), 1568 (C=C), 1309 (C=S), 1204 and 1030 (C–O); 1H 
NMR (DMSO-d6, 200 MHz):  = 3.274 (d, 1H, J = 9.2 Hz,  
–CH2–pyrazoline), 3.709 (s, 3H, OCH3), 3.725 (s, 3H, OCH3), 
3.850 (s, 6H, OCH3), 3.893–3.796 (m, 1H, –CH2–pyrazoline), 
5.883 (d, 1H, J = 4.6 Hz, –CH–pyrazoline), 6.593 (s, 2H, ArH), 
6.856 (d, 1H, J = 4.4Hz, ArH), 7.189 (t, 2H, J = 4.4, 4.2 Hz, 
ArH), 7.263 (s, 2H, ArH), 7.498 (t, 2H, J = 4.2, 2.4 Hz, ArH), 
8.994 (s, 1H, ArOH), 10.089 (s, 1H, NH); 13C NMR (100 MHz, 
CDCl3):  = 42.8, 56, 56.30, 61.0, 63.0, 104.30, 111.10, 112, 
115.13, 115.36, 117, 127.17, 127.25, 135, 140.66,146.28, 





Yield: 77 %; MP: 194 °C: MF: C26H25N3O5Cl2S; IR (KBr, cm–1): 
3401 (OH), 3296 (NH), 2929 (C=C–H), 1595 (C=N), 1569 
(C=C), 1333 (C=S), 1237 and 1031 (C–O); 1H NMR (DMSO-d6, 
200 MHz):  = 3.302 (d, 1H, J = 12.6 Hz, –CH2–pyrazoline), 
3.708 (s, 3H, OCH3), 3.726 (s, 3H, OCH3), 3.842 (s, 6H, OCH3), 
3.897 (t, 1H, J = 5.8, 3.6 Hz, –CH2–pyrazoline), 5.86 (d, 1H, J 
= 4.8 Hz, –CH–pyrazoline), 6.601 (s, 2H, ArH), 6.853 (d, 1H, 
J = 4.2 Hz, ArH), 7.240 (s, 2H, ArH), 7.451 (d, 1H, J = 3.6 Hz, 
ArH), 7.667 (d, 1H, J = 4.4 Hz, ArH), 7.721 (s, 1H, ArH), 8.986 





Yield: 84 %; MP: 198 °C; MF: C27H26N4O5S; IR (KBr, cm–1): 
3398 (OH), 3311 (NH), 2993 (C=C–H), 2835 (C–H), 2227 
(C≡N), 1603 (C=N), 1580 (C=C), 1309 (C=S), 1225 and 1030 
(C–O); 1H NMR (DMSO-d6, 200 MHz): ):  = 3.314 (d, 1H, J = 
6.4 Hz –CH2–pyrazoline), 3.716 (s, 3H, OCH3), 3.724 (s, 3H, 
OCH3), 3.857 (s, 6H, OCH3), 3.907 (t, 1H, J = 5.6, 3.6 Hz,  
–CH2–pyrazoline), 5.918 (s, 1H, J = 4.4 Hz, –CH–pyrazoline), 
6.596 (s, 2H), 6.861 (d, 1H, J = 4.4 Hz, ArH), 7.274 (s, 2H, 
ArH), 7.802 (d, 2H, J = 4.2 Hz, ArH), 7.945 (d, 2H, J = 4.2 Hz, 
ArH), 8.995 (s, 1H, ArOH), 10.343 (s, 1H, NH); 13C NMR (100 
MHz, CDCl3):  = 43, 56, 56.42, 61.0, 63.25, 105, 107, 112, 
113, 117, 119, 124, 126.05, 132.27, 135, 141, 144, 146.78, 





Yield: 86 %; MP: 250 °C; MF: C27H29N3O5S; IR (KBr, cm–1): 
3401 (OH), 3300 (NH), 2922 (C=C–H), 1595 (C=N), 1570 
(C=C), 1307 (C=S), 1223 and 1030 (C–O); 1H NMR (DMSO-d6, 
200 MHz):  = 2.297 (s, 3H, CH3), 3.258 (t, 1H, J = 1.2, 8 Hz, 
–CH2–pyrazoline), 3.705 (s, 3H, OCH3), 3.722 (s, 3H, OCH3), 
3.846 (s, 6H, OCH3), 3.863 (d, 1H, J = 7 Hz, –CH2–pyrazoline), 
5.885 (d, 1H, J = 4.4 Hz, –CH–pyrazoline), 6.591 (s, 2H, ArH), 
6.852 (d, 1H, J = 4.2 Hz, ArH), 7.154 (d, 2H, J = 4.0 Hz, ArH), 
7.258 (s, 2H, ArH), 7.364 (d, 2H, J = 4.0 Hz, ArH), 8.984 (s, 





Yield: 92 %; MP: 242 °C; MF: C27H29N3O5S: IR (KBr, cm–1): 
3395 (OH), 3294 (NH), 2930 (C=C–H), 1595 (C=N), 1570 
(C=C), 1316 (C=S), 1213 and 1033 (C–O): 1H NMR (DMSO-d6, 
200 MHz):  = 2.238 (s, 3H, –CH3), 3.247 (d, 1H, J = 9.2 Hz,  
–CH2–pyrazoline), 3.699 (s, 3H, OCH3), 3.727 (s, 3H, OCH3), 
3.836 (s, 6H, OCH3), 3.884–3.836 (m, 1H, –CH2–pyrazoline), 
5.872 (d, 1H, J = 4.4 Hz, –CH–pyrazoline), 6.594 (s, 2H, ArH), 
6.854 (d, 1H, J = 4.0 Hz, ArH), 7.250–7.192 (m, 6H, ArH), 





Yield: 92 %; MP: 238 °C; MF: C27H29N3O6S; IR (KBr, cm–1): 
3420 (OH), 3292 (NH), 2929 (C=C–H), 2852 (C–H), 1595 
(C=N), 1570 (C=C), 1316 (C=S), 1212.68 and 1024 (C–O); 1H 
NMR (DMSO-d6, 200 MHz):  = 3.318–3.274 (m, 1H, –CH2–
pyrazoline), 3.894–3.715 (m, 15H, OCH3), 3.922–3.859 (m, 
1H, –CH2–pyrazoline), 5.892 (d, 1H, J = 5.6Hz, –CH–
pyrazoline), 6.591 (s, 2H, ArH), 6.948–6.845 (m, 2H, ArH), 
7.191–7.080 (m, 4H, ArH), 8.146 (d, 1H, J = 4.0 Hz, ArH), 
8.962 (s, 1H, ArOH), 9.923 (s, 1H, NH); 13C NMR (CDCl3, 100 
MHz):  = 42.7, 56, 56.14, 61.0, 63, 104.14, 110.25, 111.0, 
112.0, 117.14, 120.4, 121.7, 124.4, 126.34, 128.54, 135.21, 






Yield: 87 %; MP: 268 °C; MF: C26H26N3O5ClS; IR (KBr, cm–1): 
3390 (OH), 3300 (NH), 2930 (C=C–H), 2852 (C–H), 1595 
(C=N), 1569 (C=C), 1335 (C=S), 1224 and 1030 (C–O);  
1H NMR (DMSO-d6, 200 MHz):  = 3.333–3.259 (m, 1H,  
–CH2–pyrazoline), 3.709 (s, 3H, OCH3), 3.723 (s, 3H, OCH3), 
3.851 (s, 6H, OCH3), 3.875 (d, 1H, J = 9.6 Hz, –CH2–
pyrazoline), 5.889 (d, 1H, J = 4.8 Hz, –CH–pyrazoline), 6.587 
(s, 2H, ArH), 6.854 (d, 2H, J = 4.2 Hz, ArH), 7.263 (s, 2H, ArH), 
7.404 (d, 2H, J = 4.2 Hz, ArH), 7.579 (d, 2H, J = 4.2 Hz, ArH), 





Yield: 89 %; MP: 278 °C; MF: C26H26N4O7S; IR (KBr, cm–1): 
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(C=S), 1233 and 1021 (C–O), 1504 (NO2 asym), 1364 (NO2 
sym); 1H NMR (DMSO-d6, 200 MHz):  = 3.34 (d, 1H, J = 4.4 
Hz, –CH2–pyrazoline), 3.724 (s, 6H, OCH3), 3.862 (s, 6H, 
OCH3), 3.946–3.90 (m, 1H, –CH2–pyrazoline), 5.934 (d, 1H, 
J = 5.2 Hz, –CH–pyrazoline), 6.607 (s, 2H, ArH), 6.866 (d, 1H, 
J = 4.2 Hz, ArH), 7.285 (s, 2H, ArH), 8.049 (d, 2H, J = 4.2 Hz, 
ArH), 8.222 (d, 2H, J = 4.2 Hz, ArH), 8.998 (s, 1H, ArOH), 
10.480 (s, 1H, NH); 13C NMR (CDCl3, 100 MHz):  = 42.79, 
56, 56.44, 61.0, 63.32, 112, 113, 117, 123, 124, 126, 135, 






Yield: 86 %; MP: 252oC; MF: C26H27N3O5S: IR (KBr, cm–1): 
3378 (OH), 2930 (C=C–H), 1592 (C=N), 1567 (C=C), 1309 
(C=S), 1227 and 1033 (C–O); 1H NMR (DMSO-d6, 200 MHz): 
 = 3.272 (d, 1H, J = 9.4 Hz, –CH2–pyrazoline), 3.708 (s, 3H, 
OCH3), 3.725 (s, 3H, OCH3), 3.794 (s, 6H, OCH3), 3.896–
3.665 (m, 1H, –CH2–pyrazoline), 5.899 (d, 1H, J = 5Hz, –CH–
pyrazoline), 6.599 (s, 2H, ArH), 6.857 (d, 1H, J = 4.2Hz, ArH), 
7.187 (t, 1H, J = 3.4Hz, J = 3.6Hz, ArH), 7.265 (s, 2H, ArH), 
7.354 (t, 2H, J = 3.6Hz, 3.8Hz, ArH), 7.519 (d, 2H, J = 3.6Hz, 
ArH), 8.984 (s, 1H, ArOH), 10.086 (s, 1H, NH); 13C NMR (100 
MHz, CDCl3):  = 42.67, 56, 56.47, 61.0, 63.34,105.12, 
112.23, 113.02, 117, 125.40, 126.15, 127, 128.35, 136, 
140.29, 146.96, 147.06, 153.39, 155.61, 174; MS: m / z 494 
(M+1). 
 
GENERAL PROCEDURE FOR THE PREPARATION OF N1-
PHENYL SULFONYLPYRAZOLINE (6a–e) 
To a suspension of 5-(4,5-dihydro-3-(3,4,5-trimethoxy-
phenyl)-1H-pyrazol-5-yl)-2-methoxyphenol 4a (1 mmol) in 
5 mL absolute ethanol, substituted phenyl sulphonyl chlo-
ride (1 mmol) was added and the mixture stirred at reflux. 
The progress of the reaction was monitored by TLC. After 
completion of reaction (1 h), the mixture was allowed to 
cool at room temperature. The solid precipitated was fil-
tered, washed with hot ethanol (2 × 3mL), and dried under 




Yield: 80 %; MP: 210 °C; MF: C25H25N3O9S; IR (KBr, cm–1): 
3370 (OH), 2929 (C=C–H), 2837 (C–H), 1575 (C=N), 1538 
(C=C), 1178 and 1057 (C–O), 1369 (S=O asym), 1178 (S=O 
sym), 1509 (NO2 asym), 1324 (NO2 sym); 1H NMR (400 MHz, 
CDCl3):  = 3.210 (dd, 1H, J = 7.2 Hz, J = 6.8 Hz, –CH2–pyrazo-
line), 3.712 (dd, 1H, J = 2.8, 11.2 Hz, –CH2–pyrazoline), 3.907–
3.898 (m, 12H, OCH3), 5.409 (dd, 1H, J = 6.8 Hz, J = 7.2 Hz, –
CH2–pyrazoline), 5.649 (s, 1H, ArOH), 6.828 (d, 2H, J = 8 Hz, 
ArH), 6.961–6.926 (m, 4H, ArH), 7.711–7.561 (m, 3H, ArH), 
8.094 (d, 1H, J = 7.2Hz, ArH); 13C NMR (100 MHz, CDCl3):  
= 43.8, 56.0, 56.31, 61.0, 64.3, 104.4, 111.0, 113.0, 118.3, 
123.63, 125.9, 129.7, 131.05, 132.0, 133.7, 134.08, 140.5, 




Yield: 88 %; MP: 160 °C; MF: C25H25N2O7ClS; IR (KBr, cm–1): 
3387 (OH), 2931 (C=C–H), 1572 (C=N), 1509 (C=C), 1169 and 
1056 (C–O), 1362 (S=O asym), 1169 (S=O sym); 1H NMR (400 
MHz, CDCl3, in ppm):  = 3.150 (dd, 1H, J = 8, 8 Hz, –CH2–
pyrazoline), 3.548 (dd, 1H, J = 11.2, 11.2 Hz, –CH2–
pyrazoline), 3.916 (s, 6H, OCH3), 3.906 (s, 6H, OCH3), 4.911 
(dd, 1H, J = 8, 8 Hz, –CH2–pyrazoline), 5.640 (s, 1H, ArOH), 
6.881–6.791 (m, 3H, ArH), 6.927 (s, 2H, ArH), 7.447–7.413 
(m, 2H, ArH), 7.786–7.752 (m, 2H, ArH); 13C NMR (100 MHz, 
CDCl3):  = 43.8, 56.01, 56.4, 61.0, 65.0, 104.3, 110.54, 
112.9, 118.64, 126.0, 129.01, 129.7, 133.4, 134.7, 139.7, 






Yield: 74 %; MP: 156 °C; MF: C25H24N2O7ClFS: IR (KBr, cm–1): 
3402 (OH), 2932 (C=C–H), 1575 (C=N), 1511 (C=C), 1178 and 
1087 (C–O), 1369 (S=O asym), 1233 (S=O sym); 1H NMR (400 
MHz, CDCl3):  = 3.206 (dd, 1H, J = 7.2, 7.2 Hz, –CH2–
pyrazoline), 3.617 (dd, 1H, J = 11.2, 11.2 Hz, –CH2–
pyrazoline), 3.960–3.911 (m, 12H, OCH3), 5.041 (dd, 1H, J = 
6.8, 7.2 Hz, –CH2–pyrazoline), 5.628 (s, 1H, ArOH), 6.850–
6.716 (m, 3H, ArH), 6.939 (s, 2H, ArH), 7.201 (t, 1H, J = 8.4, 





Yield: 82%; MP: 208 °C: MF: C25H25N3O9S: IR (KBr, cm–1): 
3403 (OH), 2929 (C=C–H), 1594 (C=N), 1568 (C=C), 1171 and 
1023 (C–O), 1345 (S=O asym), 1171 (S=O sym), 1503 (NO2 
asym), 1345(NO2 sym): 1H NMR (400 MHz, CDCl3, in ppm): 
 = 3.118 (dd, 1H, J = 9.6, 11.2 Hz, –CH2–pyrazoline), 3.548 
(m, 1H, –CH2–pyrazoline), 3.840–3.780 (m, 12H, OCH3), 
4.980 (dd, 1H, J = 9.2, 10.8 Hz, –CH2–pyrazoline), 6.639–
6.583 (m, 3H, ArH), 6.871–6.843 (m, 2H, ArH), 7.259 (s, 1H, 
ArOH), 7.841–7.791 (m, 2H, ArH), 8.166–8.115 (m, 1H, 





Yield: 77 %; MP: 229 °C; MF: C25H25N2O7ClS: IR (KBr, cm–1): 
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(C=C), 1176 and 1057 (C–O), 1367 (S=O asym), 1176 (S=O 
sym); 1H NMR (400 MHz, CDCl3):  = 3.172 (dd, 1H, J = 7.6 Hz, 
J = 7.6 Hz, –CH2–pyrazoline), 3.647 (dd, 1H, J = 11.2, 11.6 Hz, 
–CH2–pyrazoline), 3.877–3.852 (m, 12H, OCH3), 5.351 (dd, 
1H, J = 7.6, 8.0 Hz, –CH–pyrazoline), 6.182 (s, 1H, ArOH), 6.79 
(d, 1H, J = 8.0 Hz, ArH), 6.893 (d, 4H, J = 10.8 Hz, ArH), 7.370–
7.330 (m, 1H, ArH), 7.492–7.438 (m, 2H, ArH), 8.052 (d, 1H,  
J = 8.0 Hz, ArH); HRMS: m / z 533.1148(M+H). 
 
GENERAL PROCEDURE FOR THE PREPARATION OF 
PYRIMIDINE DERIVATIVE (7a) 
To a suspension of (E)-3-(3-hydroxy-4-methoxyphenyl)-1-
(3,4,5-trimethoxyphenyl)prop-2-en-1-one 3a (1 mmol) in  
5 mL absolute ethanol was added 10 % sodium hydroxide 
(NaOH) under ice cold condition and stirred for 5 min. 
Guanidine hydrochloride (1 mmol) was added in one 
portion and the mixture stirred at reflux. The progress of 
the reaction was monitored by TLC. After completion of 
reaction (24 h), the reaction mixture was poured in ice-cold 
water, neutralized with dilute HCl until precipitation occurs. 
The precipitate so obtained was filtered, washed with 
water and purified by column chromatography using 




Yield: 77 %; MP: 202 °C; MF: C20H21N3O5: IR (KBr, cm–1): 
3496 and 3394 (NH), 2933 (C=C–H), 1603 (C=N), 1573 (C=C), 
1219 and 1022 (C–O); 1H NMR (DMSO-d6, 200 MHz):  = 
3.350 (s, 3H, OCH3), 3.848 (s, 3H, OCH3), 3.90 (s, 6H, OCH3), 
6.602 (s, 2H, –NH2), 7.032 (d, 1H, J = 4 Hz, ArH), 7.478 (s, 
2H, ArH), 7.565 (s, 1H, ArH), 7.690 (s, 1H, ArH), 7.710 (s, 1H, 
Pyrazole–H), 9.162 (s, 1H, ArOH); 13C NMR (CDCl3, 100 
MHz):  = 56.01, 56.28, 60.95, 103.41, 104.3, 110.72, 
113.51, 119.43, 130.83, 133.35, 140.07, 146.0, 149.02, 
153.41, 163.4, 165.51, 165.63; HRMS: 384.1554 (M+H). 
Anticancer Activity 
THE PROCEDURE OF THE SRB-ASSAY 
Cytotoxic potencies in cancer cell lines MCF-7 and K562 
were carried by sulforhodamine B (SRB) assay method. [23] 
Tumor cells (human breast cancer cell line MCF-7) were 
grown in tissue culture flasks in growth medium (RPMI-
1640 with 2 mM glutamine, pH 7.4, 10 % fetal calf serum, 
100 mg mL–1 streptomycin, and 100 units mL–1 penicillin) at 
37 °C under the atmosphere of 5 % CO2 and 95 % relative 
humidity employing a CO2 incubator. The cells at the sub-
confluent stage were harvested from the flask by treatment 
with trypsin (0.05 % trypsin in PBS containing 0.02 % EDTA) 
and placed in growth medium. The cells with more than 97 % 
viability (trypan blue exclusion) were used for cytotoxicity 
studies. An aliquot of 100 mL of cells was transferred to a 
well of 96-well tissue culture plate. The cells were allowed 
to grow for one day at 37 °C in a CO2 incubator as men-
tioned above. The test materials at different concentra-
tions were then added to the wells and cells were further 
allowed to grow for another 48h. Suitable blanks and posi-
tive controls were also included. Each test was performed 
in triplicate. The cell growth was stopped by gently layering 
of 50 mL of 50 % trichloroacetic acid. The plates were incu-
bated at 4 °C for an hour to fix the cells attached to the bot-
tom of the wells. Liquids of all the wells were gently 
pipetted out and discarded. The plates were washed five 
times with doubly distilled water to remove TCA, growth 
medium, etc and were air-dried. 100 mL of SRB solution (0.4 
% in 1 % acetic acid) was added to each well and the plates 
were incubated at ambient temperature for half an hour. 
The unbound SRB was quickly removed by washing the 
wells five times with 1 % acetic acid. Plates were air dried, 
tris-buffer (100 mL of 0.01 M, pH 10.4) was added to all the 
wells and plates were gently stirred for 5 min on a mechan-
ical stirrer. The optical density was measured on ELISA 
reader at 540 nm. The cell growth in the absence of any test 
material was considered 100 % and in turn, growth inhibi-
tion was calculated. GI50 values were determined by regres-
sion analysis.  
Antioxidant Activity 
DPPH RADICAL SCAVENGING ACTIVITY  
The ability of compounds to scavenge DPPH radical was as-
sessed using Ramanathan Sambath Kumar et al method[24] 
with modification. Briefly, 1 mL of synthesized compounds 
as 1 mM was mixed with 3.0 mL DPPH (0.5 mmol L–1 in 
methanol), the resultant absorbance was recorded at 517 nm 
after 30 min incubation at 37 °C. The percentage of scav-
enging activity was derived using the following formula,  
 
Percentage inhibition (%) = [(Acontrol – Asample) / Acontrol] × 100 
 
where Acontrol is absorbance of DPPH; Asample is absorbance 
of the reaction mixture (DPPH with Sample). 
 
NO RADICAL SCAVENGING ACTIVITY 
NO radical scavenging activity of compounds was carried 
out as per the method of Ramanathan Sambath Kumar et 
al.[22] NO radicals were generated from sodium nitroprus-
side solution. 1 mL of 10 mM sodium nitroprusside was 
mixed with 1 mL of 1 mM synthetic compounds in phos-
phate buffer (0.2 M, pH 7.4). The mixture was incubated at 
25 °C for 150 min. After incubation the reaction mixture 
mixed with 1.0 mL of pre-prepared Griess reagent (1 % 
sulphanilamide, 0.1 % naphthyl ethylenediamine dichloride 
and 2 % phosphoric acid). The absorbance was measured at 
546 nm and the percent inhibition was calculated using the 
same formula as above. The decreasing absorbance indi-
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SUPEROXIDE RADICAL (SOR) SCAVENGING ASSAY 
The superoxide anion scavenging activity was performed by 
the reported method.[25] The reaction mixture consisting of 
1 mL of nitro blue tetrazolium (NBT) solution (156 mM NBT 
in phosphate buffer, pH 7.4), 1 mL NADH solution (468 mM 
NADH in phosphate buffer, pH 7.4), and 1 mL of synthetic 
compound (1 mM) solution was mixed. The reaction was 
started by adding 1 mL of phenazine methosulfate (PMS) 
solution (60 mM PMS in phosphate buffer, pH 7.4) to the 
mixture. The reaction mixture was incubated at 25 °C for  
5 min and the absorbance was measured at 560 nm against 
the blank sample and compared with standard and 
percentage of inhibition was calculated using the same 
formula as above. The decreased absorbance of the reaction 
mixture indicated increased SOR scavenging activity.  
 
HYDROGEN PEROXIDE (H2O2) SCAVENGING ACTIVITY 
The hydrogen peroxide scavenging assay carried out by the 
reported method.[26] A solution of hydrogen peroxide  
(40 mM) prepared in phosphate buffer (pH 7.4). The 1 mM 
concentrations of various synthetic compounds added to a 
hydrogen peroxide solution (0.6 mL, 40 mM). The absorb-
ance of hydrogen peroxide at 230 nm was determined after 
10 min. against a blank solution containing phosphate 
buffer without the drug. The percentage scavenging of 
hydrogen peroxide by synthetic compounds and standard 
compounds calculated by using the following formula,  
 
Percentage scavenged (H2O2) = (A0 – A1) / A0  × 100 
 
where, A0 = the absorbance of control; A1 = the absorbance 
in presence of the sample of MO and standards. 
Anti-inflammatory Activity 
IN VITRO ANTI-INFLAMMATORY ACTIVITY BY PROTEIN 
DENATURATION METHOD 
The reaction mixture (10 mL) consisted of 0.4 mL of egg 
albumin (from fresh hen’s egg), 5.6 mL of phosphate 
buffered saline (PBS, pH 6.4) and 4 mL of synthetic 
compound (1 mM). A similar volume of double-distilled 
water served as control. Then the mixtures were incubated 
at 37 °C for 15 min and then heated at 70 °C for 5 min. After 
cooling, their absorbance was measured at 660 nm by using 
the vehicle as blank. Diclofenac sodium (1 mM) was used as 
the reference standard and treated similarly for the 
determination of absorbance. The percentage inhibition of 
protein denaturation was calculated by the formula, 
 
% inhibition = 100 × (Vt / Vc – 1) 
 
where, Vt = absorbance of test sample, Vc = absorbance of 
control.[27]  
 
RESULTS AND DISCUSSION 
Chemistry 
In the present study, we report three categories of novel 
analogs of CA-4 having the same substituent on ring A and 
B with different bridgehead linker, such as 3,5-diaryl-1-car-
bothioamide-pyrazoline (5a–j), N1-phenyl sulfonyl pyrazo-
line (6a–e) and pyrimidine 7a. The target compounds (5a–
j) and (6a–e) was accomplished through the reaction be-
tween 4a with differently substituted phenyl isothiocya-



























































5f : R = 2-CH3
5g: R = 2-OCH3
5h: R = 4-Cl
5i : R = 4-NO2
5j : R = H
6a : R = 2-NO2
6b: R = 4-Cl
6c: R = 3-F,4-Cl
6d: R = 4-NO2
6e: R = 2-Cl  
Scheme 1. Reagents and conditions: (i) NaOH, Ethanol, rt, 24 h; (ii) H2NNH2·H2O, Ethanol, 70–80 °C, 16 h;  
(iii) Phenyl isothiocynate, Ethanol, 70–80 °C, 60 min; (iv)  Phenyl Sulphonyl Chloride, Ethanol, 70–80 °C, 1h;  
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1). The starting compound viz. pyrazoline analog of CA-4 4a 
for the synthesis of the target compounds was achieved 
from its precursor chalcone analog of CA-4 3a in good yield 
as per the literature precedent.[12,13] On the other hand, 
compound 7a was synthesized by treating compound 3a 
with guanidine hydrochloride in the presence of sodium hy-
droxide via 1,4-addition with subsequent rearrangement. 
The structural investigation of all the synthesized com-




All the synthesized compounds were evaluated for their in 
vitro cytotoxic potencies in human breast cancer cell line 
MCF-7, besides compound 7a was also evaluated against 
human myeloid leukemia cell line K562 using the sulforho-
damine B (SRB) assay method. Adriamycin, an effective an-
ticancer drug was used as a reference standard. During the 
screening process, three response parameters (GI50, TGI, 
and LC50) were determined. The GI50 value (growth inhibi-
tory activity) refers to the concentration of the compound 
causing 50% reduction in net cell growth, the TGI value 
(cytostatic activity) fix the concentration of the compound 
needed for total growth inhibition, and the LC50 value 
(cytotoxic activity) is the concentration of the compound 
that causes net 50 % loss of initial cells. The calculated re-
sponse parameters for all the compounds against MCF-7 
and for 7a against K562 are presented in Table 1. Corre-
sponding to the GI50 values, a compound’s activity is classi-
fied as inactive, > 100 µM; moderate, between > 10 and  
< 100 µM; and active, < 10 µM. 
 Among the three categories of novel analogs of com-
bretastatin-A4, most of the compounds have shown notice-
able cytotoxicity against MCF-7 with the concentration of 
the drug that produced 50 % inhibition of cell growth (GI50). 
Compound 7a, in particular, showed significant cytotox-
ocity (GI50 < 0.1 µM) against the MCF-7 cell line equal to 
that of adriamycin (GI50 <0.1 µM) whereas, compounds 6c, 
5j, and 5g also displayed good cytotoxicity (GI50 = 25.3–42.6 
µM). However, all other compounds showed weak cytotox-
icity (GI50 = 58.6–100 µM) against MCF-7 cell line. 
 A similar relationship of the TGI concentrations of 
the compounds in comparison with adriamycin was also 
carried. Although most of the compounds were inactive, 
yet compounds 7a (TGI = 38.58 µM) was found to be most 
active and compound 5d (TGI = 86.5 µM) exhibited weak 
activity against the MCF-7 cell line. All the other com-
pounds were found inactive (TGI > 100 μM) as compared to 
standard drug adriamycin. Furthermore, the LC50 concen-
trations of the compounds were compared with adriamycin 
to get an insight into the cytotoxic effects of these com-
pounds against the MCF-7 cell line. All the compounds (LC50 
>100 µM) like adriamycin (LC50 = 97.1 µM) were inactive 
against the MCF-7 cell line. 
 Encouraged by the appreciable cytotoxicity exhib-
ited by compound 7a against MCF-7, it was soon after sub-
jected to evaluate cytotoxicity against human myeloid 
leukemia cell line K562. The results obtained was remarka-
ble with GI50 < 0.1 µM, comparable to that of standard drug 
adriamycin (GI50 < 0.1 µM). The TGI concentrations of the 
compound (TGI >100 µM) was less significant to that of 
adriamycin (TGI = 75.8 µM). The LC50 concentrations of  
the compound 7a (LC50 > 100 µM) as like adriamycin (LC50 >  
100 µM) appeared higher against the K562 cell line. 
 SAR study reveals that (chalcone analog of CA-4) 3a 
(GI50 < 0.1 µM) with the same substituents on ring A and B 
was as potent as that of adriamycin, consistent with the IC50 
= 4.3 nM, and 0.9 µM against K562[11] and MCF-7[28] cell 
 
Table 1. In vitro anticancer screening of compounds against 
MCF-7(a) and K562(a) cell lines. 
Entry R 
MCF-7 K 562 
LC50(b) TGI(c) GI50(d) LC50(b) TGI(c) GI50(d) 
3a – > 100 > 100 < 0.1 NT NT NT 
4a – > 100 > 100 76.7 NT NT NT 
5a 4-OCH3 > 100 > 100 85.9 NT NT NT 
5b 4-F > 100 > 100 > 100 NT NT NT 
5c 2,4-Cl > 100 > 100 58.6 NT NT NT 
5d 4-CN > 100 > 100 87.2 NT NT NT 
5e 4-CH3 > 100 > 100 59.1 NT NT NT 
5f 2-CH3 > 100 > 100 83.8 NT NT NT 
5g 2-OCH3 > 100 > 100 42.6 NT NT NT 
5h 4-Cl > 100 > 100 85.9 NT NT NT 
5i 4-NO2 > 100 > 100 > 100 NT NT NT 
5j H > 100 99.69 34.75 NT NT NT 
6a 2-NO2 > 100 > 100 68.6 NT NT NT 
6b 4-Cl > 100 > 100 71.1 NT NT NT 
6c 3-F, 4-Cl > 100 86.5 25.3 NT NT NT 
6d 4-NO2 > 100 > 100 89.9 NT NT NT 
6e 2-Cl > 100 > 100 > 100 NT NT NT 
7a – > 100 38.58 < 0.1 > 100 > 100 < 0.1 
Adriamycin – > 100 > 100 < 0.1 > 100 75.8 < 0.1 
(a) aConcentrations in µM.  
(b) Concentration of drug resulting in a 50 % reduction in the measured 
protein at the end of the drug treatment as compared to that at the 
beginning calculated from [(Ti – Tz)/ Tz] × 100 = –50. 
(c) Drug concentration resulting in total growth inhibition (TGI) will 
calculated from Ti = Tz.  
(d) Growth inhibition of 50 % (GI50) calculated from [(Ti – Tz) /(C – Tz)] × 100 
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lines respectively. However, (pyrazoline analog of CA-4) 4a 
(GI50 = 76.7 µM) showed poor cytotoxicity.  An increase in 
activity was observed when phenyl sulfonyl or phenyl 
carbothioamide group was substituted at N1-position of 
pyrazoline ring. Compound 6c, 5j, 5g, 5c, 5e, 6a, and 6b 
showed better cytotoxicity than that of 4a. Furthermore, 
pyrimidine analog of CA-4 7a displayed significant cytotox-
icity against both K562 and MCF-7 cell line. From this evi-
dences, a general specific trend in structure and activity 
cannot be established. Since, chalcone and pyrazoline ana-
log of CA-4 adopt twisted geometry[11,12] like that of CA-4, 
which is indispensable to fit into the binding site of tubulin 
to inhibit tubulin polymerization. However, among the syn-
thesized pyrazoline analog (5a–j) and (6a–g), none of the 
compounds was as a potent as that of CA-4. On the con-
trary, the pyrimidine analog 7a being coplanar, established 
from the available characterization data, could act by a dif-
ferent mechanism to disclose its cytotoxicity, since a small 
change in the structure of CA-4 analog has shown the sur-
prising effect on other biological targets.[29]  
 
ANTI-INFLAMMATORY ACTIVITY 
Denaturation of proteins is a well- known recognized basis 
of inflammation. In this study, all the synthesized 
compounds were evaluated for in vitro anti-inflammatory 
activity by protein denaturation of egg albumin method 
and results are presented in Table 2. Compound 6a and 6d 
showed good inhibition (81.65–79.81 %) compared to the 
diclofenac sodium, a standard anti-inflammation drug 
(90.21 %) at 1mM concentration. Compounds 6b, 5b, 6c, 
and 6e showed effective inhibition of heat-induced albumin 
denaturation (76.14–72.47 %). However, rest of the 
compounds showed moderate inhibition. 
 
ANTIOXIDANT ACTIVITY 
Overproduction of reactive oxygen species (ROS) 
contributes to pathophysiology associated with various 
inflammatory disorders.[30] These radicals can cause dam-
age to cell components such as proteins, lipids, sugars and 
nucleotides,[13] and may compel the cell from performing its 
normal physiological functions together with induction of 
oxidative stress. Antioxidants are the compounds capable 
of scavenging the free radicals, an option to combat against 
excessively generated free radicals. Therefore, all the syn-
thesized compound 3a, 4a, (5a–j), (6a–e) and 7a were eval-
uated against a variety of reactive oxygen and nitrogen 
species such as 2,2-diphenyl-2-picrylhydrazyl (DPPH), nitric 
oxide (NO), superoxide (SOR) and hydrogen peroxide 
(H2O2). Free radical scavenging activity was determined as 
percent inhibition and results are summarized in Table 2. 
All the synthesized compounds have shown good to excel-
lent scavenging activity against DPPH, NO and SOR 
radicals.  
 Among the series, compound 6c, 6d, and 6e (56.66–
61.11 %) were excellent inhibitors of DPPH radical, com-
pared to standard drug ascorbic acid (44.18 %) whereas 
compound 5d showed (43.33 %) moderate inhibition of 
DPPH radical. However, rests of the compounds were de-
void of activity. 
 In case of NO radical scavenging activity, compounds 
3a, 4a, 5f, 6a, 6b, 6c, 6d, and 6e showed excellent activity 
(46.66–61.66 %) as compared to standard drug ascorbic 
acid (42.63 %). Besides, compounds 5e and 5a exhibited 
moderate activity (41.80–34.42 %) whereas, the remaining 
compounds were inactive.  
 The SOR scavenging activity results revealed that 
most of the synthesized compound displayed remarkable 
activity except, compound 5i and 6e (35.71–39.28 %). Com-
pounds 3a, 4a, 5a–h, 5j, and 6a–d found to possess excel-
lent SOR scavenging activity (78.57–92.85 %) compared to 
a standard drug ascorbic acid (74.07 %). 




inflammatory Antioxidant activity 
% inhibition (1 mM) 
Egg albumin DPPH NO SOR H2O2 
3a – 64.22 23.33 51.66 85.71 28.82 
4a – 69.72 30.00 46.66 91.07 44.49 
5a 4-OCH3 66.97 21.11 40.00 92.85 29.37 
5b 4-F 74.31 23.33 31.66 87.50 17.67 
5c 2,4-Cl 49.54 15.55 08.33 91.07 06.65 
5d 4-CN 58.71 43.33 5.00 89.28 22.96 
5e 4-CH3 63.30 23.33 41.66 92.85 41.72 
5f 2-CH3 72.47 20.00 50.00 92.85 42.38 
5g 2-OCH3 69.72 11.11 25.00 91.07 28.25 
5h 4-Cl 61.46 23.33 33.33 85.71 26.21 
5i 4-NO2 55.96 05.00 05.00 35.71 13.76 
5j H 61.46 21.11 23.33 78.57 40.33 
6a 2-NO2 81.65 34.44 61.66 85.71 32.61 
6b 4-Cl 76.14 30.00 55.00 82.14 43.02 
6c 3-F, 4-Cl 74.31 56.66 56.66 83.92 38.95 
6d 4-NO2 79.81 53.33 56.66 89.28 36.51 
6e 2-Cl 72.47 61.11 53.33 38.28 37.59 
7a – 64.22 15.55 61.66 91.07 37.80 
Control – – – – – – 
AA – – 44.18 42.63 74.07 47.17 
DS – 90.21 – – – – 
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 On the contrary, all compounds evaluated against 
hydrogen peroxide demonstrated well to moderate activ-
ity. Compounds 4a, 5e, 5f, 5j, and 6b (40.33–44.49 %) 
showed good activity as compared to reference standard 
ascorbic acid (47.17 %) whereas, compounds 6c, 6d, and 6e 
(36.55–38.95 %) exhibited moderate activity and all other 
compounds were poor inhibitors of H2O2 radical. 
 
CONCLUSION 
In conclusion, we have synthesized a diverse library of 
pyrazole and pyrimidine analogs of CA-4 and evaluated in 
vitro as potential antitumor, anti-inflammatory, and antiox-
idant agents. Results of the anticancer screening disclosed 
compound 7a, a potential lead candidate that possess 
potent anti-proliferative activity against MCF-7 and K562, 
with GI50 inhibitory values <0.1 µM respectively. Com-
pounds 6c, 5j and 5g also displayed good cytotoxicity 
against MCF-7 (GI50 = 25.3–42.6 µM). On the other hand, 
compound 6a and 6d showed good inhibition of protein 
denaturation (81.65–79.81 %) compared to the standard 
drug diclofenac sodium (90.21 %). However, most of the 
compounds screened were found to procure good to excel-
lent DPPH, NO and SOR radical scavenging activity. 
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